Morningstar

BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

Symptom relief sustained to three years: Improvements in the stringent endpoints HiSCR75, HiSCR90, and HiSCR100 at one year were sustained to three years in 81.2%, 64.3%, and 50.1% of patients, ...
Seeking Alpha

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

"Today's FDA approval for BIMZELX is an exciting milestone that reflects our commitment to continuously improving the standard of care in plaque psoriasis and to raising expectations of what treatment ...
Morningstar

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

"Psoriatic arthritis and axial spondyloarthritis are serious, chronic inflammatory diseases that can have a great impact in the daily lives of patients and their families. The data presented at EULAR ...